Video Transcription
Guilherme Santana 00:03
Hi everyone. My name is Guilherme Santana. I'm the CEO of Nanobioplus, and I'm going to present our achievements so far. Nanobioplus is a company driven by science, so it's specialized in biopolymers and drug delivery systems. We are a team of mainly scientists, although we have a broad spectrum of clinicians and entrepreneurs as well. Fun fact, the founding team is actually my mom and me. She is a well-known scientist in the area. So far, we have developed and licensed three products, and we are currently working on four new products. Because of our team, we're able not just to develop a product, but to get all the way to scale up, up to designing the factory and deploying the product with our partners. Working through those strategic partnerships allows us to take products to the market faster than usual.
Right now, on our roadmap, we just finished up a factory on aesthetics, which is hyaluronic acid, one of our main areas of research. Using the same biopolymer base, we have products for orthopedic use and also ophthalmic use. Some of the innovations that I can mention, for example, are thermosensitive hyaluronic acid, which allows jellification when you are treating back issues. The products have different characteristics, although they are still hyaluronic acid, also autocross-linked, which don't have the same toxicities as current products in the market. These innovative approaches apply to regenerative medicine, which is one of the areas where we apply a lot of our research.
This is the status of our current roadmap. We have products in the market, products licensed, and some other products under development. The market that we are in is the regenerative medicine market, and those products allow the body to heal in most cases. It is a better route that we see is growing a lot right now. Our business model, as I mentioned, is pretty much to develop the product and license the product, but taking that all the way to the factory. We do all the scale-up and actually factory design. We are a bit different because we actually generate revenue. I see most companies still pre-revenue. Just last year, in royalties and R&D services, we generated over a million dollars. Right now, the mix for next year will be that the majority will be royalties, and we still have some R&D development. One of the more recent products we are entering into production in 2024 will change this mix of revenue.
Again, we are a multidisciplinary team. For example, if you Google our CTO, you're going to see more than 8,000 citations. It is a lot on Google Scholar. She has two books, 15 patents filed, and three granted already. We have three products in the market right now. The idea is to raise money to fulfill our preclinical roadmap at this point. That's pretty much my presentation. The unique value proposition of the company is the scientific knowledge around these areas that allow us to deliver the products with a lower risk profile. So that's it. Thank you.
